Functional classification of prostate cancer‑associated miRNAs through CRISPR/Cas9‑mediated gene knockout

Jiang,Fu‑Neng; Liang,Yu‑Xiang; Wei,Wang; Zou,Cui‑Yun; Chen,Guan‑Xing; Wan,Yue‑Ping; Liu,Ze‑Zhen; Yang,Yang; Han,Zhao‑Dong; Zhu,Jian‑Guo; Zhong,Wei‑De

doi:10.3892/mmr.2020.11491

Functional classification of prostate cancer‑associated miRNAs through CRISPR/Cas9‑mediated gene knockout

Authors:
- Fu‑Neng Jiang
- Yu‑Xiang Liang
- Wang Wei
- Cui‑Yun Zou
- Guan‑Xing Chen
- Yue‑Ping Wan
- Ze‑Zhen Liu
- Yang Yang
- Zhao‑Dong Han
- Jian‑Guo Zhu
- Wei‑De Zhong
View Affiliations

Affiliations: Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510180, P.R. China, Department of Urology, Guizhou Provincial People's Hospital, The Affiliated Hospital of Guizhou Medicine University, Guiyang, Guizhou 550002, P.R. China, Guangzhou Key Laboratory of Aquatic Animal Diseases and Waterfowl Breeding, Zhongkai University of Agriculture and Engineering, Guangzhou, Guangdong 510225, P.R. China, Department of Urology, Huadu District People's Hospital, Southern Medical University, Guangzhou, Guangdong 510800, P.R. China
Published online on: September 7, 2020 https://doi.org/10.3892/mmr.2020.11491
Pages: 3777-3784
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to use the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‑associated (Cas) 9‑mediated gene knockout technology for the rapid classification of the differential function of micro (mi)RNAs screened using miRNA expression profiling by microarray. The rational design of single guide RNAs for the CRISPR/Cas9 system was verified to function in human LNCaP cells with rapid and efficient target gene editing. miRNA (miR)‑205, miR‑221, miR‑222, miR‑30c, miR‑224, miR‑455‑3p, miR‑23b and miR‑505 were downregulated in patients with prostate cancer (PCa) and were experimentally validated to function as tumor suppressors in prostate cancer cells, affecting tumor proliferation, invasion and aerobic glycolysis. In addition, the data of the present study suggested that miR‑663a and mfiR‑1225‑5p were upregulated in prostate cancer tissues and cell proliferation of miR‑663a and miR‑1225‑5p knockout PCa cells was significantly lower compared with miR‑NC cells. Furthermore, knockout of miR‑1225‑5p and miR‑663a significantly decreased the lactate production in LNCaP cells in vitro. In conclusion, the present study offered a simple and efficient method for rapidly classifying miRNA function by applying CRISPR/Cas9 in LNCaP cells. The present study suggested, for the first time to the best of the authors' knowledge, that the aberrant expression of miR‑663a and miR‑1225‑5p may be involved with the progression of prostate cancer, implying their potential as candidate markers for this type of cancer. However, the precise role of miR‑663a and miR‑1225‑5p in accelerating the development of prostate cancer and promoting tumor progression remains to be elucidated.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bartel DP: MiRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ayub SG, Kaul D and Ayub T: Microdissecting the role of miRNAs in the pathogenesis of prostate cancer. Cancer Genet. 208:289–302. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zhao Y, Cong L and Lukiw WJ: Plant and Animal microRNAs (miRNAs) and their potential for inter-kingdom communication. Cell Mol Neurobiol. 38:133–140. 2018. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
7	Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 167:6130–6135. 2007. View Article : Google Scholar
8	Plaisier CL, Pan M and Baliga NS: A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res. 22:2302–2314. 2012. View Article : Google Scholar : PubMed/NCBI
9	Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ and Ding QN: The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. J Cell Biochem. 119:2763–2786. 2018. View Article : Google Scholar : PubMed/NCBI
10	He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, et al: Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics. 14:7572013. View Article : Google Scholar : PubMed/NCBI
11	Cho SW, Kim S, Kim JM and Kim JS: Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 31:230–232. 2013. View Article : Google Scholar : PubMed/NCBI
12	Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science. 339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sanjana NE, Shalem O and Zhang F: Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 11:783–784. 2014. View Article : Google Scholar : PubMed/NCBI
15	Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T and Cathomen T: A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39:9283–9293. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim JI and Kim JS: Digenome-seq: Genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods. 12:237–243. 2015. View Article : Google Scholar : PubMed/NCBI
17	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
18	Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
19	Saini S, Majid S and Dahiya R: Diet, microRNAs and prostate cancer. Pharm Res. 27:1014–1026. 2010. View Article : Google Scholar : PubMed/NCBI
20	Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A, et al: The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 8:529–538. 2010. View Article : Google Scholar : PubMed/NCBI
21	Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
22	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
23	Airley RE and Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
24	Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, et al: miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
25	Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, Deng G and Dahiya R: MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 116:5637–5649. 2010. View Article : Google Scholar : PubMed/NCBI
26	Wang N, Li Q, Feng NH, Cheng G, Guan ZL, Wang Y, Qin C, Yin CJ and Hua LX: miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl. 15:735–741. 2013. View Article : Google Scholar : PubMed/NCBI
27	Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, Noldus J, Tannapfel A and Mirmohammadsadegh A: MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 43:307–314. 2013. View Article : Google Scholar : PubMed/NCBI
28	Pang H and Yue X: MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. Tumour Biol. 39:10104283177013082017. View Article : Google Scholar : PubMed/NCBI
29	Chen S, Jin L, Nie S, Han L, Lu N and Zhou Y: MiR-205 inhibits growth and invasion of neuroblastoma by targeting cAMP responsive element binding protein 1. Oncol Res. 26:445–455. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 16:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Wang X, Wang Y, Peng R, Lin Z, Wang Y, Hu B, Wang J and Shi G: Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein. Oncol Lett. 14:363–368. 2017. View Article : Google Scholar : PubMed/NCBI
33	Huang Y, Li Y, Wang FF, Lv W, Xie X and Cheng X: Over-expressed miR-224 promotes the progression of cervical cancer via targeting RASSF8. PLoS One. 11:e01623782016. View Article : Google Scholar : PubMed/NCBI
34	He C, Wang L, Zhang J and Xu H: Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer. Mol Cancer. 16:352017. View Article : Google Scholar : PubMed/NCBI
35	Liu F, Liu Y, Shen J, Zhang G and Han J: MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Fizzled 5 expression. Oncotarget. 7:49130–49142. 2016. View Article : Google Scholar : PubMed/NCBI
36	Zhao Y, Yan M, Yun Y, Zhang J, Zhang R, Li Y, Wu X, Liu Q, Miao W and Jiang H: MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. Oncol Rep. 37:2449–2458. 2017. View Article : Google Scholar : PubMed/NCBI
37	Negrete-Garcia MC, Ramírez-Rodriguez SL, Rangel-Escareño C, Muñoz-Montero S, Kelly-García J, Vázquez-Manríquez ME, Santillán P, Ramírez MM, Ramírez-Martínez G, Ramírez- Venegas A and Ortiz-Quintero B: Deregulated MicroRNAs in cancer-associated fibroblasts from front tumor tissues of lung adenocarcinoma as potential predictors of tumor promotion. Tohoku J Exp Med Oct. 246:107–120. 2018. View Article : Google Scholar
38	Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R, et al: The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related. Oncogene. 35:4752–4761. 2016. View Article : Google Scholar : PubMed/NCBI
39	Zhang Y, Xu X, Zhang M, Wang X, Bai X, Li H, Kan L, Zhou Y, Niu H and He P: MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD. BMC Cancer. 16:3152016. View Article : Google Scholar : PubMed/NCBI
40	Zheng H, Zhang F and Lin X, Huang C, Zhang Y, Li Y, Lin J, Chen W and Lin X: MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling. Oncotarget. 7:4647–4663. 2016. View Article : Google Scholar : PubMed/NCBI